• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics announces equity grants to employees under inducement plan

April 5, 2023 By Sean Whooley

Senseonics logoSenseonics (NYSE:SENS) announced today that it made equity grants to new employees under its 2019 inducement plan.

The Germantown, Maryland-based long-term continuous glucose monitor (CGM) maker made these grants in accordance with NYSE requirements.

On April 4, 2023, Senseonics granted 13 new non-executive employees non-qualified stock options. These options enable the employees to purchase an aggregate of 200,000 shares. The employees may also purchase a restricted stock unit for 250,000 shares of common stock as an inducement to join the company.

According to a news release, the options have an exercise price of $0.5951 per share. That marks Senseonics’ common stock’s closing price on April 4. The company said that 25% of the shares underlying the options vest on the first anniversary of the employee’s start date. The remainder vest in monthly installments over the subsequent three-year period. In all cases, these remain contingent on the employee’s continued service with Senseonics at the applicable vesting date.

Senseonics said that 25% of shares underlying the restricted unit vest on the first anniversary of the employee’s start date. The remainder vest in six equal installments each on May 15 and Nov. 15. That covers the subsequent 36-month period following the first anniversary of the start date, beginning with May 15, 2024. Again, it remains subject to continuous employment through the applicable vesting date.

This marks the third time in the past year that Senseonics announced equity grants under the 2019 inducement plan. The company offered grants to 17 non-executive employees in July 2022, followed by six non-executives in October 2022.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS